Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial - Concepedia

Concepedia

Publication | Closed Access

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

329

Citations

25

References

2019

Year

Marin H. Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Ignacio Martín‐Loeches, Jean‐François Timsit, Richard G. Wunderink, Christopher Bruno, Jennifer A. Huntington,

The Lancet Infectious Diseases

AntibioticsNosocomial PneumoniaNon-inferiority TrialMedicinePhase 3

References

	Year	Citations

Page 1